Safety and Efficacy of Trospium Chloride and Solifenacin in Stroke-Induced Neurogenic Lower Urinary Tract Dysfunction: A Randomized Controlled Trial

• Published in: Neurourology and urodynamics 2024-10
• Main Authors: Hajebrahimi, Sakineh, Pourmohammad, Ali, Konstantinidis, Charalampos, Samarinas, Michael, Morsali, Soroush, Mostafaei, Hadi, Farhoudi, Mehdi, Rahnama'i, Mohammad-Sajjad, Beheshti, Rasa, Salehi-Pourmehr, Hanieh
• Format: Article
• Language: English
• ISSN: 0733-2467; 1520-6777; 1520-6777
• DOI: 10.1002/nau.25614

Neurogenic dysfunction of the lower urinary tract is one of the challenging diseases with high burdens in urology. Our study aims to evaluate the efficacy of a 4-week treatment with Solifenacin and Trospium chloride and assess their safety and impact on quality of life. Following the selection of 206 stroke patients from two centers who met specific eligibility criteria, including a clinical diagnosis of stroke, normal cognitive function, and the presence of lower urinary tract symptoms (LUTS), participants were randomly assigned to receive oral Solifenacin, Trospium chloride, or a placebo. Under the supervision of the Ethics Committee, the baseline characteristics, compliance with medication, and outcomes were monitored, gathered, and analyzed. The majority of participants were male, with a mean age of 67.3, and most had ischemic stroke. The groups had no significant difference in urinary symptoms after stroke. All of the symptoms in the study groups, according to the NBSS questionnaire, were decreased following treatment compared to the baseline (p